Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer
Clinical trial NCT02258451 · COMPLETED
Trial details
- NCT number
- NCT02258451
- Sponsor
- Bayer
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-06-04
- Primary completion
- 2020-01-22
- Enrollment
- 283
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.